An alternative strategy is to use lower targets, as defined by experts in the ongoing trial of pegylated interferon 2 alpha in MPN including MPN‐SVT aiming for a Hct ≤0·42, WBC count between 2 and 8 × 109/l, and platelet count between 100 and 200 × 109/l (Hoffman, 2012). This evidence concerns the gene IFNA2 and myeloproliferative disorder.